Uveitis refers to a group of intraocular inflammatory diseases that cause 10% to 15% of blindness in the developed world.1-4 Despite advances in immunosuppressive treatments, corticosteroids remain the mainstay of therapy.5,6 Many patients, however, are intolerant of or resistant to systemic steroids. Topical corticosteroids administered as eye drops are better tolerated than systemic corticosteroids but are typically only effective for anterior uveitis.5 Unfortunately, most of the severe vision loss related to uveitis occurs in patients with intermediate or posterior uveitis, in which the inflammation involves the vitreous and retina.5 Previously, these patients required systemic therapy, either with corticosteroids or other immunosuppressive agents, to control their ocular inflammation.5
Lowder C, Belfort R, Lightman S, et al. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis. Arch Ophthalmol. 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: